Last Price$233.1(0.2%)
Market Cap$34.6B
LTM Change in Working Capital
$97.9M
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
8/10
18.2% overvalued
ResMed Inc. Change in Working Capital
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in Working Capital | ($26.2M) | ($41.0M) | ($69.7M) | ($64.9M) | $23.1M | ($79.5M) | ($23.5M) | $46.0M | ($9,173.0K) | ($42.0M) | ($64.8M) | $61.7M | ($89.9M) | $9,062.0K | ($177.1M) | ($97.9M) | $1,405.0K | ($708.1M) | ($462.1M) | $44.8M |
Overvalued or undervalued?
Check the intrinsic value for RMD
and see if it's the right time to invest.
ResMed Inc. (RMD) Change in Working Capital comparison analysis
General
LTM Change in Working Capital
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
ResMed Inc.RMD
$97.9M
N/A
N/A
N/A
Median Peer Set
($134.1M)
0.0%
6.9%
0.0%
Hologic, Inc.HOLX
$241.9M
N/A
26.1%
N/A
Repligen CorporationRGEN
$33.7M
2,934.3%
N/A
N/A
West Pharmaceutical Services, Inc.WST
$2,900.0K
N/A
N/A
N/A
Masimo CorporationMASI
($10.7M)
(84.9%)
(30.1%)
(19.9%)
AptarGroup, Inc.ATR
($32.3M)
N/A
(42.5%)
N/A
Baxter International Inc.BAX
($236.0M)
N/A
13.6%
(11.1%)
Alcon Inc.ALC
($316.0M)
(20.1%)
0.2%
45.8%
Becton, Dickinson and CompanyBDX
($320.0M)
14.3%
152.0%
N/A
The Cooper Companies, Inc.COO
($333.7M)
52.5%
30.6%
52.8%
Intuitive Surgical, Inc.ISRG
($919.3M)
18.2%
35.7%
23.4%
RMD key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 425.5 25.4% | 607.0 42.7% | 716.3 18.0% | 835.4 16.6% | 920.7 10.2% | 1,092.4 18.6% | 1,243.1 13.8% | 1,368.5 10.1% | 1,514.5 10.7% | 1,555.0 2.7% | 1,678.9 8.0% | 1,838.7 9.5% | 2,066.7 12.4% | 2,340.2 13.2% | 2,606.6 11.4% | 2,957.0 13.4% | 3,196.8 8.1% | 3,578.1 11.9% | 4,223.0 18.0% | 4,685.3 10.9% |
| Cost of Goods Sold (COGS) | 150.6 | 230.1 | 331.8 | 341.6 | 366.9 | 436.9 | 501.8 | 547.8 | 573.8 | 565.2 | 667.5 | 772.2 | 865.0 | 978.0 | 1,070.0 | 1,239.2 | 1,357.7 | 1,553.8 | 1,867.3 | 2,030.0 |
% margin | 274.9 64.6% | 376.9 62.1% | 384.5 53.7% | 493.8 59.1% | 553.8 60.1% | 655.5 60.0% | 741.3 59.6% | 820.7 60.0% | 940.7 62.1% | 989.8 63.7% | 1,011.4 60.2% | 1,066.5 58.0% | 1,201.7 58.1% | 1,362.2 58.2% | 1,536.6 59.0% | 1,717.8 58.1% | 1,839.1 57.5% | 2,024.3 56.6% | 2,355.7 55.8% | 2,655.3 56.7% |
| Operating Expenses | 167.1 | 244.5 | 294.3 | 348.4 | 360.0 | 412.1 | 473.4 | 525.3 | 585.8 | 578.4 | 596.2 | 625.2 | 745.0 | 801.9 | 900.6 | 908.7 | 926.7 | 1,024.0 | 1,203.7 | 1,335.4 |
| Research & Development Expenses (R&D) | 30.0 | 37.2 | 50.1 | 60.5 | 63.1 | 75.2 | 92.0 | 109.7 | 120.1 | 118.2 | 114.9 | 118.7 | 144.5 | 155.1 | 180.7 | 201.9 | 225.3 | 253.6 | 287.6 | 307.5 |
| Selling, General & Administrative Expenses (SG&A) | 135.7 | 200.2 | 237.3 | 278.1 | 289.9 | 328.9 | 371.2 | 401.6 | 430.8 | 450.4 | 472.6 | 482.6 | 554.0 | 600.4 | 645.0 | 676.7 | 670.4 | 739.4 | 874.0 | 917.1 |
% margin | 97.4 22.9% | 131.3 21.6% | 90.2 12.6% | 143.0 17.1% | 190.3 20.7% | 240.4 22.0% | 266.9 21.5% | 294.4 21.5% | 354.8 23.4% | 405.1 26.1% | 409.2 24.4% | 429.0 23.3% | 425.8 20.6% | 541.8 23.2% | 579.3 22.2% | 809.7 27.4% | 903.7 28.3% | 1,000.3 28.0% | 1,131.9 26.8% | 1,319.9 28.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 27.8 | 33.9 | 38.9 | 31.2 | 26.2 | 16.9 | 17.1 | 16.4 | 2.3 | 1.0 | 0.4 | 22.3 | 47.4 | 0.0 |
| Interest Expense | 0.0 | 1.3 | 1.3 | 10.1 | 10.1 | 10.1 | 1.8 | 4.8 | 6.4 | 6.1 | 5.8 | 11.2 | 28.2 | 28.4 | 36.2 | 40.4 | 24.0 | 22.3 | 47.4 | 45.7 |
| Pre-tax Income | 96.6 | 133.4 | 98.0 | 157.9 | 201.7 | 260.6 | 303.7 | 331.9 | 385.1 | 431.1 | 435.9 | 439.6 | 418.7 | 521.3 | 518.8 | 733.1 | 883.7 | 960.5 | 1,101.7 | 1,264.8 |
% effective tax rate | 31.8 33.0% | 45.2 33.9% | 31.7 32.3% | 47.6 30.1% | 55.2 27.4% | 70.5 27.1% | 76.7 25.3% | 77.1 23.2% | 78.0 20.2% | 85.8 19.9% | 83.0 19.0% | 87.2 19.8% | 76.5 18.3% | 205.7 39.5% | 114.3 22.0% | 111.4 15.2% | 409.2 46.3% | 181.0 18.8% | 204.1 18.5% | 243.8 19.3% |
% margin | 64.8 15.2% | 88.2 14.5% | 66.3 9.3% | 110.3 13.2% | 146.4 15.9% | 190.1 17.4% | 227.0 18.3% | 254.9 18.6% | 307.1 20.3% | 345.3 22.2% | 352.9 21.0% | 352.4 19.2% | 342.3 16.6% | 315.6 13.5% | 404.6 15.5% | 621.7 21.0% | 474.5 14.8% | 779.4 21.8% | 897.6 21.3% | 1,021.0 21.8% |
| EPS | 0.47 | 0.61 | 0.43 | 0.72 | 0.97 | 1.26 | 1.49 | 1.75 | 2.15 | 2.44 | 2.51 | 2.51 | 2.42 | 2.21 | 2.83 | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 |
| Diluted EPS | 0.46 | 0.58 | 0.43 | 0.70 | 0.95 | 1.23 | 1.44 | 1.71 | 2.10 | 2.39 | 2.47 | 2.49 | 2.40 | 2.19 | 2.80 | 4.27 | 3.24 | 5.30 | 6.09 | 6.92 |
% margin | 136.9 32.2% | 174.0 28.7% | 90.2 12.6% | 204.8 24.5% | 190.3 20.7% | 322.2 29.5% | 374.3 30.1% | 422.6 30.9% | 469.8 31.0% | 484.9 31.2% | 482.3 28.7% | 522.7 28.4% | 568.9 27.5% | 680.2 29.1% | 705.8 27.1% | 990.4 33.5% | 1,099.2 34.4% | 1,176.6 32.9% | 1,358.8 32.2% | 1,533.5 32.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is ResMed Inc.'s Change in Working Capital?
As of today, ResMed Inc.'s last 12-month Change in Working Capital is $97.9M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is ResMed Inc.'s Change in Working Capital growth rate?
Over the last year, ResMed Inc.'s Change in Working Capital growth was N/A. The average annual Change in Working Capital growth rates for ResMed Inc. have been 311.6% over the past three years, N/A over the past five years.